Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII: Full Scheme Comparison and Current Status

The Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison matters for investors who came across these two close ended equity schemes while researching older mutual fund NFOs and want to know where they stand today. Both funds were structured with a fixed tenure at launch but follow different investment themes. This Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII breakdown covers category, structure, available data and present day investability of each scheme.

Click Here – Get Free Investment Predictions

Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII: Quick Comparison at a Glance

This Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII table lays out the core facts side by side so you can see how the two close ended funds differ on structure, theme and scale.

Parameter	Kotak India Growth Fund Series 7	UTI Long Term Advantage Fund Series VII
AMC	Kotak Mahindra Mutual Fund	UTI Mutual Fund
Category	Close Ended Equity, Multi Cap	Close ended equity linked savings scheme (elss) with a statutory lock in
Launch / Era	Inception date 31 August 2018, managed by Devender Singhal since January 2019	This series belongs to uti mutual fund's close ended elss nfo family
Benchmark	Nifty 200 TRI	Not confirmed in public trackers for this Series
Risk Level	Very High	Very High (typical for this category)
Last Available NAV	Around Rs 15.10 (Direct Growth, last public NAV as of August 2021)	Not publicly available for this specific option
AUM Last Reported	Not publicly confirmed for this specific plan	Not publicly available for this specific option
Current Status	Close ended scheme launched August 2018; public NAV tracking for this series thins out after 2021, consistent with maturity or wind-down of the fixed tenure	Close ended elss scheme subject to the standard tax saving lock in that applied at launch

About Kotak India Growth Fund Series 7

In this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison, Kotak India Growth Fund Series 7 is a close ended equity, multi cap scheme from Kotak Mahindra Mutual Fund. Inception date 31 August 2018, managed by Devender Singhal since January 2019, benchmarked against the Nifty 200 TRI. Close ended scheme launched August 2018; public NAV tracking for this series thins out after 2021, consistent with maturity or wind-down of the fixed tenure. That structure is the Kotak side of the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison.

About UTI Long Term Advantage Fund Series VII

The other half of this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison, UTI Long Term Advantage Fund Series VII, is a ELSS tax saving equity close ended equity linked savings scheme (ELSS) with a statutory lock in from UTI Mutual Fund. This series belongs to uti mutual fund's close ended elss nfo family. Close ended elss scheme subject to the standard tax saving lock in that applied at launch. That is the UTI side of the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison.

Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII: Key Differences Explained

The points below summarise what the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison shows once you move past scheme names and into structure.

• Investment theme: Kotak India Growth Fund Series 7 follows a close ended equity, multi cap mandate, while UTI Long Term Advantage Fund Series VII is built around ELSS tax saving equity, which is a different risk and return profile.
• AMC: Kotak India Growth Fund Series 7 comes from Kotak Mahindra Mutual Fund, while UTI Long Term Advantage Fund Series VII comes from UTI Mutual Fund, so expense structures, fund management style and distribution reach differ.
• Structure: Close ended scheme launched August 2018; public NAV tracking for this series thins out after 2021, consistent with maturity or wind-down of the fixed tenure By comparison, close ended ELSS scheme subject to the standard tax saving lock in that applied at launch
• Overall takeaway: the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison ultimately comes down to two different close ended strategies from different fund houses, and neither accepts fresh investment today.

These structural differences sit at the centre of any Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison and matter more than any single data point.

Check the Univest Screener for live fund and stock data

Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII: Are These Schemes Still Open for Fresh Investment

Both schemes in this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison were structured as close ended funds with a fixed tenure, which means neither accepts fresh lumpsum or SIP investment once the original NFO window closes. Investors who already hold units generally have to wait for maturity or a scheme merger to access their money. For Kotak India Growth Fund Series 7, close ended scheme launched august 2018; public nav tracking for this series thins out after 2021, consistent with maturity or wind-down of the fixed tenure. For UTI Long Term Advantage Fund Series VII, close ended ELSS scheme subject to the standard tax saving lock in that applied at launch. Investors seeking similar exposure today can look at UTI Mutual Fund's current open ended ELSS scheme, UTI Long Term Equity Fund, which is the practical takeaway from this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII status check.

Download the Univest iOS App or Univest Android App to track live NAV updates and screen mutual fund data on the go.

Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII: Which One Fits Your Portfolio

Since both schemes are close ended and not confirmed open for fresh investment, this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison is most useful for existing unit holders trying to understand their scheme's positioning. This Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII guidance section exists for that reason. Investors who already hold either scheme should track maturity dates, merger announcements or IDCW payouts through their AMC's official communication and consolidated account statements, since specific NAV and AUM for UTI Long Term Advantage Fund Series VII were not publicly available for this analysis. That is the core practical lesson of this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison, and it is always worth confirming details with a SEBI registered advisor before deciding.

Conclusion

The Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison shows two different close ended equity strategies, one from Kotak Mahindra Mutual Fund and the other from UTI Mutual Fund. Neither scheme is confirmed open for fresh investment today. This Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII review is a reminder to check AMC statements for the latest status on any holding. New investors exploring similar strategies should look at current open ended schemes from Kotak Mahindra Mutual Fund and UTI Mutual Fund and consult a SEBI registered advisor before investing.

Frequently Asked Questions on Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII

The common questions readers ask about the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison are answered below.

Is Kotak India Growth Fund Series 7 open for fresh investment right now?

Ans. No. In the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison, Kotak India Growth Fund Series 7 is the close ended scheme from Kotak Mahindra Mutual Fund. Close ended scheme launched August 2018; public NAV tracking for this series thins out after 2021, consistent with maturity or wind-down of the fixed tenure.

Is UTI Long Term Advantage Fund Series VII still open for investment today?

Ans. In the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison, UTI Long Term Advantage Fund Series VII is a close ended equity linked savings scheme (ELSS) with a statutory lock in. Close ended elss scheme subject to the standard tax saving lock in that applied at launch, so specific current NAV and AUM data are not publicly available.

What is the single biggest difference highlighted in the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison?

Ans. The biggest difference in the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison is investment theme. Kotak India Growth Fund Series 7 follows a close ended equity, multi cap mandate, while UTI Long Term Advantage Fund Series VII is built around ELSS tax saving equity.

Which AMC manages each fund in this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison?

Ans. Kotak India Growth Fund Series 7 is managed by Kotak Mahindra Mutual Fund, and UTI Long Term Advantage Fund Series VII is managed by UTI Mutual Fund.

What should existing investors take away from the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison?

Ans. Existing investors reading this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison should refer to their AMC statements and any maturity or merger notice for the current status of their holding.

Is there an open ended alternative to the schemes in this Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison?

Ans. For UTI Long Term Advantage Fund Series VII, investors can look at UTI Mutual Fund's current open ended ELSS scheme, UTI Long Term Equity Fund. For Kotak India Growth Fund Series 7, Kotak Mahindra Mutual Fund offers other diversified equity schemes for investors seeking similar exposure today.

What risk category applies across the Kotak India Growth Fund Series 7 vs UTI Long Term Advantage Fund Series VII comparison?

Ans. Kotak India Growth Fund Series 7 is rated Very High risk. Close ended equity schemes like UTI Long Term Advantage Fund Series VII are typically also rated Very High risk.